RU2010129291A - METHOD FOR TREATMENT AND PREVENTION OF ARTERIAL HYPERTENSION AND PHARMACEUTICAL COMPOSITION FOR TREATMENT OF ARTERIAL HYPERTENSION - Google Patents

METHOD FOR TREATMENT AND PREVENTION OF ARTERIAL HYPERTENSION AND PHARMACEUTICAL COMPOSITION FOR TREATMENT OF ARTERIAL HYPERTENSION Download PDF

Info

Publication number
RU2010129291A
RU2010129291A RU2010129291/15A RU2010129291A RU2010129291A RU 2010129291 A RU2010129291 A RU 2010129291A RU 2010129291/15 A RU2010129291/15 A RU 2010129291/15A RU 2010129291 A RU2010129291 A RU 2010129291A RU 2010129291 A RU2010129291 A RU 2010129291A
Authority
RU
Russia
Prior art keywords
antibodies
activated
angiotensin
synthase
endothelial
Prior art date
Application number
RU2010129291/15A
Other languages
Russian (ru)
Other versions
RU2525156C2 (en
Inventor
Светлана Александровна Сергеева (RU)
Светлана Александровна Сергеева
Людмила Федоровна Долговых (RU)
Людмила Федоровна Долговых
Владимир Иванович Петров (RU)
Владимир Иванович Петров
Original Assignee
Общество с ограниченной ответственностью "Научно-производственная фирма "Материа Медика Холдинг" (RU)
Общество С Ограниченной Ответственностью "Научно-Производственная Фирма "Материа Медика Холдинг"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Общество с ограниченной ответственностью "Научно-производственная фирма "Материа Медика Холдинг" (RU), Общество С Ограниченной Ответственностью "Научно-Производственная Фирма "Материа Медика Холдинг" filed Critical Общество с ограниченной ответственностью "Научно-производственная фирма "Материа Медика Холдинг" (RU)
Priority to RU2010129291/15A priority Critical patent/RU2525156C2/en
Priority to US13/135,901 priority patent/US9308275B2/en
Priority to CA2804969A priority patent/CA2804969A1/en
Priority to AU2011278039A priority patent/AU2011278039B2/en
Priority to AU2011278038A priority patent/AU2011278038B2/en
Priority to PE2013000076A priority patent/PE20130398A1/en
Priority to EA201300128A priority patent/EA201300128A1/en
Priority to MX2013000543A priority patent/MX2013000543A/en
Priority to EEP201300004A priority patent/EE201300004A/en
Priority to SG10201505561TA priority patent/SG10201505561TA/en
Priority to KR1020137003520A priority patent/KR20140009110A/en
Priority to SG2013002282A priority patent/SG187034A1/en
Priority to BR112013000840A priority patent/BR112013000840A2/en
Priority to BR112013000779A priority patent/BR112013000779A2/en
Priority to JP2013519175A priority patent/JP2013538186A/en
Priority to SE1350177A priority patent/SE1350177A1/en
Priority to NZ606767A priority patent/NZ606767A/en
Priority to DE112011102356T priority patent/DE112011102356T5/en
Priority to JP2013519177A priority patent/JP2013532183A/en
Priority to SG2013002324A priority patent/SG187038A1/en
Priority to EP11775838.3A priority patent/EP2593140A2/en
Priority to EA201300126A priority patent/EA030566B1/en
Priority to IT000640A priority patent/ITTO20110640A1/en
Priority to MX2013000544A priority patent/MX2013000544A/en
Priority to EP11779851.2A priority patent/EP2593482A2/en
Priority to CZ20130105A priority patent/CZ2013105A3/en
Priority to IT000639A priority patent/ITTO20110639A1/en
Priority to GB1302649.7A priority patent/GB2495884B/en
Priority to FR1156482A priority patent/FR2962656A1/en
Priority to PCT/IB2011/002350 priority patent/WO2012007845A2/en
Priority to CN2011800443324A priority patent/CN103108657A/en
Priority to DE112011102358T priority patent/DE112011102358T5/en
Priority to US13/135,882 priority patent/US8703124B2/en
Priority to PCT/IB2011/002391 priority patent/WO2012007846A2/en
Priority to CA2804966A priority patent/CA2804966A1/en
Priority to GB1302656.2A priority patent/GB2496795A/en
Priority to UAA201300107A priority patent/UA114699C2/en
Priority to ES201390006A priority patent/ES2440393R1/en
Priority to SE1350184A priority patent/SE1350184A1/en
Priority to FR1156474A priority patent/FR2962654A1/en
Priority to KR1020137003861A priority patent/KR20140014059A/en
Priority to EEP201300006A priority patent/EE201300006A/en
Priority to ARP110102578A priority patent/AR082247A1/en
Priority to ARP110102577A priority patent/AR084707A1/en
Publication of RU2010129291A publication Critical patent/RU2010129291A/en
Priority to CL2013000099A priority patent/CL2013000099A1/en
Priority to NO20130217A priority patent/NO20130217A1/en
Priority to NO20130222A priority patent/NO20130222A1/en
Priority to DKPA201370080A priority patent/DK201370080A/en
Priority to LT2013016A priority patent/LT5988B/en
Priority to DKPA201370079A priority patent/DK201370079A/en
Priority to FI20135145A priority patent/FI20135145L/en
Priority to FI20135143A priority patent/FI20135143L/en
Application granted granted Critical
Publication of RU2525156C2 publication Critical patent/RU2525156C2/en
Priority to US15/060,202 priority patent/US20160251448A1/en
Priority to US15/060,157 priority patent/US20160244531A1/en
Priority to JP2016135750A priority patent/JP2016216483A/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

1. Способ лечения и профилактики артериальной гипертензии путем введения в организм лекарственного средства на основе активированной-потенцированной формы сверхмалых доз аффинно очищенных антител к рецептору ангиотензина II, приготовленную путем многократного последовательного разведения и внешнего воздействия, характеризующийся тем, что дополнительно одновременно и сочетано вводят активированную-потенцированную форму сверхмалых доз аффинно очищенных антител к эндотелиальной NO-синтазе. ! 2. Способ по п.1, характеризующийся тем, что используют активированную-потенцированную форму антител к C-концевому фрагменту AT1-рецептора ангиотензина II и активированную-потенцированную форму антител к эндотелиальной NO-синтазе. ! 3. Способ по п.1 или 2, характеризующийся тем, что активированную-потенцированную форму антител к C-концевому фрагменту AT1-рецептора ангиотензина II и активированную-потенцированную форму антител к эндотелиальной NO-синтазе используют в виде активированного-потенцированного водного или водно-спиртового раствора каждого компонента, полученного в процессе последовательного многократного разведения в водном или водно-спиртовом растворителе и промежуточного внешнего механического воздействия - вертикального встряхивания. ! 4. Способ по п.1 или 2, характеризующийся тем, что используют приготовленные в виде единого лекарственного препарата - одной лекарственной формы - смесь различных гомеопатических разведений антител к C-концевому фрагменту AT1-рецептора ангиотензина II в сочетании со смесью различных гомеопатических разведений антител к эндотелиальной NO-синтазе. !5. Способ по п.1 или 2, характер 1. A method for the treatment and prevention of arterial hypertension by introducing into the body a drug based on an activated-potentiated form of ultra-low doses of affinity-purified antibodies to the angiotensin II receptor, prepared by repeated serial dilution and external exposure, characterized in that the activated- potentiated form of ultra-low doses of affinity-purified antibodies to endothelial NO synthase. ! 2. The method according to claim 1, characterized in that they use an activated-potentiated form of antibodies to the C-terminal fragment of the AT1 receptor of angiotensin II and an activated-potentiated form of antibodies to endothelial NO synthase. ! 3. The method according to claim 1 or 2, characterized in that the activated-potentiated form of antibodies to the C-terminal fragment of the AT1 receptor for angiotensin II and the activated-potentiated form of antibodies to endothelial NO synthase are used in the form of an activated-potentiated aqueous or aqueous an alcoholic solution of each component obtained in the course of successive multiple dilutions in an aqueous or hydroalcoholic solvent and an intermediate external mechanical action - vertical shaking. ! 4. The method according to claim 1 or 2, characterized in that use is made of a mixture of different homeopathic dilutions of antibodies to the C-terminal fragment of the AT1 receptor of angiotensin II in combination with a mixture of different homeopathic dilutions of antibodies to those prepared as a single drug - one dosage form endothelial NO synthase. !5. The method according to claim 1 or 2, nature

Claims (11)

1. Способ лечения и профилактики артериальной гипертензии путем введения в организм лекарственного средства на основе активированной-потенцированной формы сверхмалых доз аффинно очищенных антител к рецептору ангиотензина II, приготовленную путем многократного последовательного разведения и внешнего воздействия, характеризующийся тем, что дополнительно одновременно и сочетано вводят активированную-потенцированную форму сверхмалых доз аффинно очищенных антител к эндотелиальной NO-синтазе.1. A method for the treatment and prevention of arterial hypertension by introducing into the body a drug based on an activated-potentiated form of ultra-low doses of affinity-purified antibodies to the angiotensin II receptor, prepared by repeated serial dilution and external exposure, characterized in that the activated- potentiated form of ultra-low doses of affinity-purified antibodies to endothelial NO synthase. 2. Способ по п.1, характеризующийся тем, что используют активированную-потенцированную форму антител к C-концевому фрагменту AT1-рецептора ангиотензина II и активированную-потенцированную форму антител к эндотелиальной NO-синтазе.2. The method according to claim 1, characterized in that they use an activated-potentiated form of antibodies to the C-terminal fragment of the AT 1 angiotensin II receptor II and an activated-potentiated form of antibodies to endothelial NO synthase. 3. Способ по п.1 или 2, характеризующийся тем, что активированную-потенцированную форму антител к C-концевому фрагменту AT1-рецептора ангиотензина II и активированную-потенцированную форму антител к эндотелиальной NO-синтазе используют в виде активированного-потенцированного водного или водно-спиртового раствора каждого компонента, полученного в процессе последовательного многократного разведения в водном или водно-спиртовом растворителе и промежуточного внешнего механического воздействия - вертикального встряхивания.3. The method according to claim 1 or 2, characterized in that the activated-potentiated form of antibodies to the C-terminal fragment of AT 1 angiotensin II receptor and the activated-potentiated form of antibodies to endothelial NO synthase are used in the form of an activated-potentiated aqueous or aqueous -alcohol solution of each component obtained in the process of successive multiple dilutions in an aqueous or aqueous-alcohol solvent and an intermediate external mechanical action - vertical shaking. 4. Способ по п.1 или 2, характеризующийся тем, что используют приготовленные в виде единого лекарственного препарата - одной лекарственной формы - смесь различных гомеопатических разведений антител к C-концевому фрагменту AT1-рецептора ангиотензина II в сочетании со смесью различных гомеопатических разведений антител к эндотелиальной NO-синтазе.4. The method according to claim 1 or 2, characterized in that use is made of a mixture of various homeopathic dilutions of antibodies to the C-terminal fragment of the AT 1 angiotensin II receptor II in combination with a mixture of various homeopathic dilutions of antibodies prepared as a single drug to endothelial NO synthase. 5. Способ по п.1 или 2, характеризующийся тем, что используют фармацевтическую композицию на основе активированной-потенцированной формы сверхмалых доз аффинно очищенных антител к C-концевому фрагменту AT1-рецептора ангиотензина II и к эндотелиальной NO-синтазе в сочетании с известными стандартными лекарственными средствами, применяемыми для лечении заболеваний сердечно-сосудистой системы следующих групп: β-адреноблокаторы, ингибиторы АПФ, в т.ч. комбинированные, диуретики, нитраты.5. The method according to claim 1 or 2, characterized in that they use a pharmaceutical composition based on an activated-potentiated form of ultra-low doses of affinity purified antibodies to the C-terminal fragment of the AT 1 angiotensin II receptor and to endothelial NO synthase in combination with known standard drugs used to treat diseases of the cardiovascular system of the following groups: β-blockers, ACE inhibitors, including combined, diuretics, nitrates. 6. Лекарственное средство для лечения и профилактики артериальной гипертензии на основе активированной-потенцированной формы сверхмалых доз аффинно очищенных антител к рецептору ангиотензина II, характеризующееся тем, что выполнено в виде фармацевтической композиции и дополнительно содержит в качестве усиливающего компонента активированную-потенцированную форму антител к эндотелиальной NO-синтазе.6. A drug for the treatment and prevention of hypertension based on an activated-potentiated form of ultra-low doses of affinity-purified antibodies to the angiotensin II receptor, characterized in that it is made in the form of a pharmaceutical composition and additionally contains an activated-potentiated form of antibodies to endothelial NO as a reinforcing component synthase. 7. Лекарственное средство по п.6, характеризующееся тем, что активированную-потенцированную форму антител к рецептору ангиотензина II и к эндотелиальной NO-синтазе используют в виде активированного-потенцированного водного или водно-спиртового раствора, полученного в процессе последовательного многократного разведения матричного раствора соответствующих антител в водном или водно-спиртовом растворителе и промежуточного внешнего механического воздействия - вертикального встряхивания.7. The drug according to claim 6, characterized in that the activated-potentiated form of antibodies to the angiotensin II receptor and to endothelial NO synthase is used in the form of an activated-potentiated aqueous or aqueous-alcoholic solution obtained by sequential multiple dilutions of the matrix solution of the corresponding antibodies in an aqueous or aqueous-alcoholic solvent; and intermediate external mechanical action - vertical shaking. 8. Лекарственное средство по п.6 или 7, характеризующееся тем, что фармацевтическая композиция выполнена в твердой лекарственной форме и содержит эффективное количество нейтрального носителя, насыщенного смесью активированной-потенцированной формы антител к рецептору ангиотензина II и активированной-потенцированной формы антител к эндотелиальной NO-синтазе, и фармацевтически приемлемые добавки.8. The drug according to claim 6 or 7, characterized in that the pharmaceutical composition is in solid dosage form and contains an effective amount of a neutral carrier saturated with a mixture of the activated-potentiated form of antibodies to the angiotensin II receptor and the activated-potentiated form of antibodies to endothelial NO- synthase, and pharmaceutically acceptable additives. 9. Лекарственное средство по п.6 или 7, характеризующееся тем, что водные или водно-спиртовые растворы активированных-потенцированных форм антител к рецептору ангиотензина II и к эндотелиальной NO-синтазе получены путем многократного последовательного разведения и промежуточного внешнего воздействия из матричных растворов аффинно очищенных антител к рецептору ангиотензина II и к эндотелиальной NO-синтазе с концентрацией 0,5÷5,0 мг/мл.9. The drug according to claim 6 or 7, characterized in that aqueous or aqueous-alcoholic solutions of activated-potentiated forms of antibodies to the angiotensin II receptor and to endothelial NO synthase are obtained by repeated serial dilution and intermediate external exposure from affinity purified matrix solutions antibodies to the angiotensin II receptor and to endothelial NO synthase with a concentration of 0.5 ÷ 5.0 mg / ml. 10. Лекарственное средство по п.6 или 7, характеризующееся тем, что каждый из компонентов сверхмалых доз аффинно очищенных антител используют в виде смеси различных, преимущественно сотенных, гомеопатических разведений.10. The drug according to claim 6 or 7, characterized in that each of the components of ultra-low doses of affinity-purified antibodies is used as a mixture of various, mainly hundred, homeopathic dilutions. 11. Лекарственное средство по п.8, характеризующееся тем, что фармацевтически приемлемые добавки включают лактозу, целлюлозу микрокристаллическую и магния стеарат. 11. The drug of claim 8, characterized in that the pharmaceutically acceptable additives include lactose, microcrystalline cellulose and magnesium stearate.
RU2010129291/15A 2010-07-15 2010-07-15 Method of treatment and prevention of arterial hypertension and pharmaceutical composition for treatment of arterial hypertension RU2525156C2 (en)

Priority Applications (55)

Application Number Priority Date Filing Date Title
RU2010129291/15A RU2525156C2 (en) 2010-07-15 2010-07-15 Method of treatment and prevention of arterial hypertension and pharmaceutical composition for treatment of arterial hypertension
US13/135,901 US9308275B2 (en) 2010-07-15 2011-07-15 Method of increasing the effect of an activated-potentiated form of an antibody
CA2804969A CA2804969A1 (en) 2010-07-15 2011-07-15 A combination pharmaceutical composition and methods of treating diseases or conditions associated with the cardiovascular system
AU2011278039A AU2011278039B2 (en) 2010-07-15 2011-07-15 A combination pharmaceutical composition and methods of treating diseases or conditions associated with the cardiovascular system
AU2011278038A AU2011278038B2 (en) 2010-07-15 2011-07-15 A method of increasing the effect of an activated-potentiated form of an antibody
PE2013000076A PE20130398A1 (en) 2010-07-15 2011-07-15 A METHOD TO INCREASE THE EFFECT OF AN ACTIVE ENHANCED FORM OF AN ANTIBODY
EA201300128A EA201300128A1 (en) 2010-07-15 2011-07-15 COMBINED PHARMACEUTICAL COMPOSITION AND METHODS FOR THE TREATMENT OF DISEASES OR CONDITIONS ASSOCIATED WITH DISABILITY OF THE CARDIOVASCULAR SYSTEM
MX2013000543A MX2013000543A (en) 2010-07-15 2011-07-15 Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract.
EEP201300004A EE201300004A (en) 2010-07-15 2011-07-15 A combined pharmaceutical composition for the treatment of diseases or conditions of the cardiovascular system
SG10201505561TA SG10201505561TA (en) 2010-07-15 2011-07-15 A Method Of Increasing The Effect Of An Activated-Potentiated Form Of An Antibody
KR1020137003520A KR20140009110A (en) 2010-07-15 2011-07-15 A combination pharmaceutical composition and methods of treating diseases or conditions associated with the cardiovascular system
SG2013002282A SG187034A1 (en) 2010-07-15 2011-07-15 A combination pharmaceutical composition and methods of treating diseases or conditions associated with the cardiovascular system
BR112013000840A BR112013000840A2 (en) 2010-07-15 2011-07-15 method for enhancing the effect of potentiated activated form of antibody to biological endogenous molecule, pharmaceutical composition and use of combination of endogenous biological molecule with potentiated activated form of antibody to endothelial synthase.
BR112013000779A BR112013000779A2 (en) 2010-07-15 2011-07-15 combination pharmaceutical compositions, patient treatment methods and use of activated potentiated form of angiotensin ii receptor 1 antibody and activated potentiated form of endothelial synthase antibody
JP2013519175A JP2013538186A (en) 2010-07-15 2011-07-15 Method for increasing the effect of activation-enhancing antibodies
SE1350177A SE1350177A1 (en) 2010-07-15 2011-07-15 Pharmaceutical combination composition and methods for treating diseases or conditions associated with the cardiovascular system.
NZ606767A NZ606767A (en) 2010-07-15 2011-07-15 A method of increasing the effect of an activated-potentiated form of an antibody
DE112011102356T DE112011102356T5 (en) 2010-07-15 2011-07-15 A combination pharmaceutical composition and method for treating diseases or conditions associated with the cardiovascular system
JP2013519177A JP2013532183A (en) 2010-07-15 2011-07-15 Combination pharmaceutical composition and method for treating diseases or conditions associated with the cardiovascular system
SG2013002324A SG187038A1 (en) 2010-07-15 2011-07-15 A method of increasing the effect of an activated-potentiated form of an antibody
EP11775838.3A EP2593140A2 (en) 2010-07-15 2011-07-15 A method of increasing the effect of an activated-potentiated form of an antibody
EA201300126A EA030566B1 (en) 2010-07-15 2011-07-15 Method of increasing therapeutic effectiveness of an activated-potentiated form of an antibody to an endogenous biological molecule and pharmaceutical composition
IT000640A ITTO20110640A1 (en) 2010-07-15 2011-07-15 PHARMACEUTICAL COMPOSITION OF COMBINATION AND METHODS FOR TREATING PATHOLOGIES OR PATHOLOGICAL STATES ASSOCIATED WITH THE CARDIOVASCULAR SYSTEM
MX2013000544A MX2013000544A (en) 2010-07-15 2011-07-15 A combination pharmaceutical composition and methods of treating diseases or conditions associated with the cardiovascular system.
EP11779851.2A EP2593482A2 (en) 2010-07-15 2011-07-15 A combination pharmaceutical composition and methods of treating diseases or conditions associated with the cardiovascular system
CZ20130105A CZ2013105A3 (en) 2010-07-15 2011-07-15 Method of increasing effect of antibody activated potentiated form
IT000639A ITTO20110639A1 (en) 2010-07-15 2011-07-15 METHOD TO INCREASE THE EFFECT OF AN ACTIVE-ENHANCED SHAPE OF AN ANTI-BODY
GB1302649.7A GB2495884B (en) 2010-07-15 2011-07-15 A method of increasing the effect of an activated-potentiated form of an antibody
FR1156482A FR2962656A1 (en) 2010-07-15 2011-07-15 METHOD FOR INCREASING THE EFFECT OF AN ACTIVATED-POTENTIALIZED FORM OF ANTIBODY
PCT/IB2011/002350 WO2012007845A2 (en) 2010-07-15 2011-07-15 A method of increasing the effect of an activated-potentiated form of an antibody
CN2011800443324A CN103108657A (en) 2010-07-15 2011-07-15 A method of increasing the effect of an activated-potentiated form of an antibody
DE112011102358T DE112011102358T5 (en) 2010-07-15 2011-07-15 A method of increasing the effect of an activated-potentiated form of an antibody
US13/135,882 US8703124B2 (en) 2010-07-15 2011-07-15 Combination pharmaceutical composition and methods of treating diseases or conditions associated with the cardiovascular system
PCT/IB2011/002391 WO2012007846A2 (en) 2010-07-15 2011-07-15 A combination pharmaceutical composition and methods of treating diseases or conditions associated with the cardiovascular system
CA2804966A CA2804966A1 (en) 2010-07-15 2011-07-15 A method of increasing the effect of an activated-potentiated form of an antibody
GB1302656.2A GB2496795A (en) 2010-07-15 2011-07-15 A combination pharmaceutical composition and methods of treating diseases or conditions associated with the cardiovascular system
UAA201300107A UA114699C2 (en) 2010-07-15 2011-07-15 A combination pharmaceutical composition and methods of treating diseases or conditions associated with the cardiovascular system
ES201390006A ES2440393R1 (en) 2010-07-15 2011-07-15 A METHOD FOR INCREASING THE EFFECT OF A POTENTIATED ACTIVATED FORM OF AN ANTIBODY
SE1350184A SE1350184A1 (en) 2010-07-15 2011-07-15 PROCEDURE TO INCREASE THE EFFECT OF AN ACTIVATED, POTENTIZED FORM OF AN ANTIBODY
FR1156474A FR2962654A1 (en) 2010-07-15 2011-07-15 PHARMACEUTICAL ASSOCIATION COMPOSITION AND USES THEREOF FOR TREATING DISEASES OR DISORDERS ASSOCIATED WITH THE CARDIOVASCULAR SYSTEM
KR1020137003861A KR20140014059A (en) 2010-07-15 2011-07-15 A method of increasing the effect of an activated-potentiated form of an antibody
EEP201300006A EE201300006A (en) 2010-07-15 2011-07-15 A pharmaceutical composition for enhancing the effect of an activated and potentiated form of an antibody
ARP110102578A AR082247A1 (en) 2010-07-15 2011-07-18 A METHOD FOR INCREASING THE EFFECTS OF A POTENTIATED ACTIVATED FORM OF AN ANTIBODY
ARP110102577A AR084707A1 (en) 2010-07-15 2011-07-18 A PHARMACEUTICAL COMBINATION COMPOSITION TO TREAT DISEASES OR CONDITIONS ASSOCIATED WITH THE CARDIOVASCULAR SYSTEM
CL2013000099A CL2013000099A1 (en) 2010-07-15 2013-01-10 A method of increasing the effect of an potentiated active form of an antibody to an endogenous biological molecule, comprising the combination of the endogenous biological molecule with an enhanced active form of an endoltelial non-synthase antibody; composition that understands it.
NO20130217A NO20130217A1 (en) 2010-07-15 2013-02-08 A pharmaceutical combination composition and methods for treating diseases or conditions associated with the cardiovascular system
NO20130222A NO20130222A1 (en) 2010-07-15 2013-02-08 Process for increasing the effect of an activated-potentiated form of an antibody
DKPA201370080A DK201370080A (en) 2010-07-15 2013-02-14 A combination pharmaceutical composition and methods of treating diseases or conditions associated with the cardiovascular system
LT2013016A LT5988B (en) 2010-07-15 2013-02-14 A method of increasing the effect of an activated-potentiated form of an antibody
DKPA201370079A DK201370079A (en) 2010-07-15 2013-02-14 A method of increasing the effect of an activated-potentiated form of an antibody
FI20135145A FI20135145L (en) 2010-07-15 2013-02-15 Pharmaceutical combination composition and methods for treating diseases or conditions related to the cardiovascular system
FI20135143A FI20135143L (en) 2010-07-15 2013-02-15 A method of increasing the potency of an activated potentiated form of an antibody
US15/060,202 US20160251448A1 (en) 2010-07-15 2016-03-03 Method of increasing the effect of an activated-potentiated form of an antibody
US15/060,157 US20160244531A1 (en) 2010-07-15 2016-03-03 Method of increasing the effect of an activated-potentiated form of an antibody
JP2016135750A JP2016216483A (en) 2010-07-15 2016-07-08 Method of increasing effect of activated-potentiated antibody

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2010129291/15A RU2525156C2 (en) 2010-07-15 2010-07-15 Method of treatment and prevention of arterial hypertension and pharmaceutical composition for treatment of arterial hypertension

Publications (2)

Publication Number Publication Date
RU2010129291A true RU2010129291A (en) 2012-01-20
RU2525156C2 RU2525156C2 (en) 2014-08-10

Family

ID=45785347

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2010129291/15A RU2525156C2 (en) 2010-07-15 2010-07-15 Method of treatment and prevention of arterial hypertension and pharmaceutical composition for treatment of arterial hypertension

Country Status (1)

Country Link
RU (1) RU2525156C2 (en)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2181297C2 (en) * 2000-06-20 2002-04-20 Эпштейн Олег Ильич Method of treatment of pathological syndrome and medicinal agent
RU2201254C1 (en) * 2001-09-25 2003-03-27 Эпштейн Олег Ильич Method for treating pathological syndrome and medicinal preparation
RU2201255C1 (en) * 2001-12-26 2003-03-27 Эпштейн Олег Ильич Medicinal agent and method of regulation of vascular tonus
UA40587U (en) * 2005-06-30 2009-04-27 Иван Николаевич Ермоленко Pneumo-hydraulic feeding system of propulsion unit
RU2309732C1 (en) * 2006-03-13 2007-11-10 Олег Ильич Эпштейн Pressed solid oral formulation of medicinal preparation and method for preparing solid oral formulation of medicinal preparation
RU2391980C1 (en) * 2008-10-22 2010-06-20 Новосибирский институт органической химии им. Н.Н. Ворожцова Сибирского отделения Российской академии наук (НИОХ СО РАН) (статус государственного учреждения) Medication for arterial hypertension and cardiac dysrhythmia treatment

Also Published As

Publication number Publication date
RU2525156C2 (en) 2014-08-10

Similar Documents

Publication Publication Date Title
RU2013136350A (en) PHARMACEUTICAL COMPOSITION CONTAINING OPIOID AGONIST AND SECKED ANTAGONIST
RU2010129291A (en) METHOD FOR TREATMENT AND PREVENTION OF ARTERIAL HYPERTENSION AND PHARMACEUTICAL COMPOSITION FOR TREATMENT OF ARTERIAL HYPERTENSION
RU2011127059A (en) NEUROTROPIC MEDICINE AND METHOD OF TREATMENT OF ORGANIC DISEASES OF THE NERVOUS SYSTEM, PSYCHOORGANIC SYNDROME AND ENCEPHALOPATHY OF VARIOUS GENESIS
RU2011127052A (en) METHOD FOR TREATING THE HEAD-VARIABLE OF VARIOUS GENESIS, KINETOSIS AND VEGETOVASCULAR DYSTONIA (OPTIONS) AND MEDICINAL PRODUCT
RU2011110106A (en) METHOD FOR TREATING CHRONIC HEART FAILURE AND PHARMACEUTICAL COMPOSITION FOR TREATING CHRONIC HEART FAILURE
RU2010129290A (en) METHOD FOR TREATING CHRONIC HEART FAILURE AND PHARMACEUTICAL COMPOSITION FOR COMPLEX THERAPY OF CHRONIC HEART FAILURE
RU2010129292A (en) METHOD FOR TREATING VEGETAIN VASCULAR DISTONIA AND PHARMACEUTICAL COMPOSITION FOR TREATMENT OF VEGETAIN VASCULAR DISTONIA
RU2010133053A (en) INTEGRATED MEDICINE FOR TREATMENT OF VIRAL DISEASES AND METHOD OF TREATMENT OF VIRAL DISEASES
RU2011127058A (en) MEDICINE FOR TREATMENT OF ALZHEIMER'S DISEASE AND METHOD OF TREATMENT OF ALZHEIMER'S DISEASE
RU2010133052A (en) INTEGRATED MEDICINE FOR TREATMENT OF VIRAL INFECTIONS AND METHOD OF TREATMENT OF VIRAL INFECTIONS
RU2011134414A (en) FULVIC ACID COMBINATION FOR TREATMENT OF VARIOUS CONDITIONS AND DISEASES
RU2010130353A (en) MEDICINE FOR TREATMENT OF ALZHEIMER'S DISEASE AND METHOD OF TREATMENT OF ALZHEIMER'S DISEASE
RU2010129295A (en) MEDICINAL PRODUCT FOR TREATING PROSTATE DISEASES AND METHOD FOR TREATING PROSTATE DISEASES
RU2010129294A (en) MEDICINE FOR TREATMENT OF ERECTILE DYSFUNCTIONS AND METHOD OF TREATMENT OF ERECTILE DYSFUNCTIONS
RU2013154072A (en) MEDICINE FOR TREATMENT OF KINETOSIS AND METHOD OF TREATMENT OF KINETOSIS
RU2010130358A (en) MEDICINE FOR TREATMENT OF ATTENTION DEFICIENCY SYNDROME AND METHOD FOR TREATMENT OF ATTENTION DEFICIENCY SYNDROME
RU2010130355A (en) MEDICINAL PRODUCT AND METHOD FOR TREATMENT OF ORGANIC DISEASES OF THE NERVOUS SYSTEM, PSYCHOORGANIC SYNDROME AND ENCEPHALOPATHY OF VARIOUS GENESIS
RU2013152871A (en) DIABETES TREATMENT METHOD AND COMBINED MEDICINE
RU2013154073A (en) PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING A PATHOLOGICAL SYNDROME
RU2013154070A (en) METHOD FOR TREATMENT OF VEGETAIN-VASCULAR DISTONIA AND MEDICINAL PRODUCT
RU2010130356A (en) MEDICINAL PRODUCT AND METHOD FOR TREATMENT OF VEGETO-VASCULAR DYSTONIA, VERTAIN SYNDROME OF VARIOUS GENESIS AND KINETOSIS
RU2010130350A (en) METHOD FOR TREATING DEPENDENCE ON PSYCHOACTIVE SUBSTANCES, ALCOHOLISM AND TOBACCO SMOKING AND MEDICINAL PRODUCT FOR TREATING DEPENDENCE ON PSYCHOACTIVE SUBSTANCES, ALCOHOLISM AND TOBACCO SMOKING
RU2010130352A (en) PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING ACUTE AND CHRONIC DISEASES OF THE RESPIRATORY SYSTEM AND COUGH SYNDROME
RU2013154071A (en) MEDICINAL PRODUCT AND METHOD FOR TREATMENT OF HEAD-WAYS
RU2011124809A (en) MEDICINE FOR TREATMENT OF PATHOLOGICAL SYNDROME AND METHOD FOR TREATING FUNCTIONAL INTESTINAL DISORDERS

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20130118

FZ9A Application not withdrawn (correction of the notice of withdrawal)

Effective date: 20140120

MM4A The patent is invalid due to non-payment of fees

Effective date: 20160716